Tags: Cancer | Imbruvica | chronic lymphocytic leukemia | blood cancer

New Leukemia Drug Works in Trial

Tuesday, 07 January 2014 12:19 PM


Pharmacyclics Inc said its cancer drug, Imbruvica, met its main goal of increasing patients' survival without their cancer worsening in a late-stage trial.
The company's stock rose 5 percent at $110.60 on Tuesday on the Nasdaq after the company said an independent safety committee recommended an early halt of the trial.
The drug was being tested in patients with chronic lymphocytic leukemia, a rare form of blood cancer that primarily affects people aged 65 and older.
Pharmacyclics said it informed the U.S. Food and Drug Administration of the committee's recommendations, while its partner, Johnson & Johnson unit Janssen had informed the European regulators.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Pharmacyclics Inc said its cancer drug, Imbruvica, met its main goal of increasing patients' survival without their cancer worsening in a late-stage trial. The company's stock rose 5 percent at $110.60 on Tuesday on the Nasdaq after the company said an independent safety...
Imbruvica,chronic lymphocytic leukemia,blood cancer
103
2014-19-07
Tuesday, 07 January 2014 12:19 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved